Lifeloc posts 12% sales growth but pushes saliva THC device back to late 2027
The Colorado-based breath-testing firm's third-quarter sales rose and its loss shrank, yet its first drug-testing product now depends on funding and is nine months later than planned.
Lifeloc Technologies recorded revenue of $2.522 million for the three months to 30 September 2026, 12% more than in the same quarter of 2025. Gross margin came to 43%, and the bottom line showed a loss of $85,000, smaller than before.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Company's press release (SEC filing): Lifeloc Technologies, Inc ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.